Every day, Global University Venturing rounds up the smaller investments from across the university innovation ecosystem in its deal net.
Axial Therapeutics, a US-based neurological disease therapy developer linked to University of Tokyo, has closed a $37.3m series C round co-led by University of Tokyo’s Innovation Platform and OneVentures. The round included Taiho Ventures, the investment arm of pharmaceutical firm Taiho, as well as Autism Impact Fund, Corundum Systems Biology, Longwood Fund, Seventure Partners and Domain Associates. Axial has now raised $91.5m in total, Taiho Ventures having put up $10m to close a series B round featuring care provider Heritage…
Thierry Heles
Thierry Heles is editor-at-large of Global University Venturing and Global Corporate Venturing, and host of the Beyond the Breakthrough podcast.
